Novel Therapies for the Treatment of Inflammatory Bowel Disease
A special issue of Gastrointestinal Disorders (ISSN 2624-5647).
Deadline for manuscript submissions: 25 December 2025 | Viewed by 14
Special Issue Editors
Interests: paediatric; inflammatory bowel disease; functional gastrointestinal disorders; coeliac disease; outcome meausures; non-clinical outcomes
Special Issues, Collections and Topics in MDPI journals
Interests: inflammatory bowel disease; coeliac disease; improving Crohn’s outcomes; intestinal inflammatory biomarkers; nutritional aspects of gut diseases; host–pathogen interactions in the gut (and how these relate to chronic gut diseases)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
It is well known that inflammatory bowel disease can be a heterogenous condition with great diversity in presentation, disease course, and response to treatment. For patients that have a poor treatment response or experience adverse events relating to certain drug regimens, novel efficacious therapies may be utilised to provide symptom relief and reduce disease activity. Novel therapies include emerging treatments that are still in the experimental stage, newly approved therapies, treatments that have been effective in other inflammatory conditions and have a role in IBD, and isolated therapies that have been successfully implemented for certain individuals.
We invite papers that report quantified outcomes on the implementation of novel therapies and welcome original studies, systematic reviews and meta-analyses, case-reports, and scoping reviews.
Dr. Angharad Hurley (Vernon-Roberts)
Prof. Dr. Andrew Day
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastrointestinal Disorders is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammatory bowel disease
- treatment/therapies
- disease activity
- remission
- symptom resolution
- drugs
- nutrition.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
